Matthew D Ringel, MD
Physician
Specialty:Endocrinology, Diabetes & Metabolism
Gender: Male
Leadership Title: Ralph W. Kurtz Chair Chair, Department of Molecular Medicine and Therapeutics Co-Director, Thyroid Cancer Unit Co-Leader, Cancer Biology Program
Academic Title: Professor in the College of Medicine
Research Program: Cancer Biology
I am the director of the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University. I also serve as co-leader of the Cancer Biology Program at the OSUCCC – James and hold the Ralph W. Kurtz Chair in Hormonology. As a specialist in thyroid cancer, my research is focused on molecular mechanisms involved in thyroid cancer invasion and metastasis, with an active interest in new drug testing for thyroid cancer therapy. Among my current research activities is serving as principal investigator (PI) for a National Cancer Institute (NCI) grant-funded study of the role of p21-activated kinases in thyroid cancer. My colleagues and I have identified a potentially important pathway (p21 activated kinase, or PAK) downstream of the BRAF gene that may be involved in the progression of papillary thyroid cancer, which is incurable when metastatic and progressive. My team hopes to determine the relevance of the PAK pathway in vivo, clarify the mechanism by which it is activated and test novel compounds that block PAK activation with the goal of determining whether PAK is a viable therapeutic target. I also served as PI for a multimillion-dollar, NCI-funded program project grant (PPG) to study genetic and signaling pathways in epithelial thyroid cancer, as well as an NCI-funded Specialized Program of Research Excellence (SPORE) grant to help improve the lives of patients with thyroid cancer. Both grants entailed several interactive projects and multiple investigators at Ohio State and other academic institutions. In addition, I have authored or co-authored numerous scientific articles in such prestigious journals as Nature Communications, Journal of the American Medical Association, Annals of Surgical Oncology and Human Molecular Genetics.
- Thyroid Diseases
- Carcinoma, Neuroendocrine
- Endocrinology
- Thyroid Cancer
- Diabetes Mellitus
- Thyroid Nodule
- Parathyroid Cancers
- Endocrine Cancers
- Neuroendocrine Tumors
- Thyroid Neoplasms
- Carcinoma
- Neoplasms
- Thyroid Nodule
- Adenoma
- Breast Neoplasms
- Neoplasm Metastasis
- Hamartoma Syndrome, Multiple
Fellowship - Endocrinology, Diabetes and Metabolism
- Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD
Internship - Internal Medicine
- MedStar Georgetown University Hospital
3800 Reservoir Rd NW, Washington, DC
Residency - Internal Medicine
- MedStar Georgetown University Hospital
3800 Reservoir Rd NW, Washington, DC
Medical School
- Pennsylvania State University at University Park
308 Old Main, University Park, PA
- Johns Hopkins Hospital
Academic Office:
1581 Dodd Dr
Columbus, Ohio 43210-1257Phone:
614-685-3333Email:
ringel.11@osu.eduPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
- October 3, 2024
RCAN1.4 regulates tumor cell engraftment and invasion in a thyroid cancer to lung metastasis-on-a-chip microphysiological system.
Nairon KG, Nigam A, Khanal T, Rodriguez MA, Rajan N, Anderson SR, Ringel MD, Skardal A
Biofabrication
September 17, 2024mLumiOpto is a Mitochondrial-Targeted Gene Therapy for Treating Cancer.
Chen K, Ernst P, Sarkar A, Kim S, Si Y, Varadkar T, Ringel MD, Liu X, Zhou L
Cancer Res
August 26, 2024Defining the Functional Sensitivity for The Siemens Atellica Calcitonin Assay: Insight from A Single-center Study.
Li J, Patton A, Lee JKY, Scheidegger M, Azaryan I, Sipos JA, Nabhan F, Jones J, Algeciras-Schimnich A, Ringel MD
Endocr Pract
August 1, 2024Recurrent malignant struma ovarii presenting as peritoneal carcinomatosis in the setting of an intact thyroid: A case report and review of the literature.
Brown M, Haight P, Ringel M, Phay J, Esnakula A, Vazzano J, Cosgrove C
Gynecol Oncol Rep
April 26, 2024Telomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype.
DeBoy EA, Nicosia AM, Liyanarachchi S, Iyer SS, Shah MH, Ringel MD, Brock P, Armanios M
Am J Hum Genet
February 28, 2024Indolent behavior of malignant Bethesda III nodules compared to Bethesda V/VI nodules.
Endo M, Peng J, Nabhan FA, Brock P, Azaryan I, Long C, Ryan LE, Ringel MD, Sipos JA
J Clin Endocrinol Metab
January 27, 2024CHEK2 founder variants and thyroid cancer risk.
Brock P, Liyanarachchi S, Nieminen TT, Chan C, Kohlmann W, Stout LA, Yao S, La Greca A, Jensen KE, Kolesar J, Salhia B, Gulhati P, Hicks JK, Ringel MD
Thyroid
December 7, 2023Presumed Pathogenic Germline and Somatic Variants in African American Thyroid Cancer.
Hurst ZA, Liyanarachchi S, Brock P, He H, Nabhan F, Veloski C, Toland AE, Ringel MD, Jhiang SM
Thyroid
December 7, 2023PDPR gene variants predisposing to papillary thyroid cancer.
Brock P, Sévigny M, Liyanarachchi S, Comiskey DF, Li W, Saarinen S, Yilmaz AS, Nieminen AII, Ringel MD, Peltomaki P, Ollila S, Nieminen TT
Thyroid
November 3, 2023Combined Vorinostat and Chloroquine Inhibit Sodium Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.
Read ML, Brookes K, Zha L, Manivannan S, Kim J, Kocbiyik M, Fletcher A, Gorvin CM, Firth G, Fruhwirth GO, Nicola JP, Jhiang S, Ringel MD, Campbell MJ, Sunassee K, Blower PJ, Boelaert K, Nieto HR, Smith VE, McCabe CJ
Clin Cancer Res
May 13, 2023A tribute to Ernest L. Mazzaferri, MD and the lasting impact that he had on thyroid cancer care ten years after his death.
Cooper DS, Ringel MD
Endocrine
April 13, 2023The RCAN1.4 metastasis suppressor is hypermethylated at intron 1 in thyroid cancer.
Khanal T, Rajan N, Li W, Liyanarachchi S, Ringel MD
Thyroid
June 4, 2022Dabrafenib vs dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer - results of a randomized, phase 2, open-label, multicenter trial.
Busaidy N, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, DeSouza JA, Poi M, Seligson ND, Cabanillas M, Sipos JA, Ringel MD, Eisfeld AK, Timmers C, Shah MH
Thyroid
April 12, 2022Serum Thyroglobulin Measurement Following Surgery without Radioactive Iodine for Differentiated Thyroid Cancer: A Systematic Review.
Chou R, Dana T, Brent GA, Goldner W, Haymart MR, Leung AM, Ringel MD, Sosa JA
Thyroid
March 11, 2022American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.
Shonka DC, Ho A, Chintakuntlawar AV, Geiger JL, Park JC, Seetharamu N, Jasim S, Ahmed AH, Bible KC, Brose MS, Cabanillas ME, Dabekaussen K, Davies L, Dias-Santagata D, Fagin JA, Faquin WC, Ghossein RA, Gopal RK, Miyauchi A, Nikiforov YE, Ringel MD, Robinson B, Ryder MM, Sherman EJ, Sadow PM, Shin JJ, Stack BC, Tuttle RM, Wirth LJ, Zafereo ME, Randolph GW
Head Neck
January 26, 2022Active surveillance versus thyroid surgery for differentiated thyroid cancer: A systematic review.
Chou R, Dana T, Haymart MR, Leung AM, Tufano R, Sosa JA, Ringel MD
Thyroid
September 30, 2021RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient.
Bagheri-Yarmand R, Busaidy NL, McBeath E, Danysh BP, Evans KW, Moss TJ, Akcakanat A, Ng PKS, Knippler CM, Golden JA, Williams MD, Multani AS, Cabanillas ME, Shaw KR, Meric-Bernstam F, Shah MH, Ringel MD, Hofmann MC
Cancers (Basel)
July 8, 2021Transcriptome analysis discloses dysregulated genes in normal appearing tumor-adjacent thyroid tissues from patients with papillary thyroid carcinoma.
He H, Liyanarachchi S, Li W, Comiskey DF, Yan P, Bundschuh R, Turkoglu AM, Brock P, Ringel MD, de la Chapelle A
Sci Rep
July 1, 2021Radioiodine: 80 years and counting; the past, present, and future.
Ringel MD
Endocr Relat Cancer
May 20, 2021Thyroid Cancer, Recent Advances in Diagnosis and Therapy.
Nabhan F, Dedhia PH, Ringel MD
Int J Cancer
January 15, 2021Prevalence of cancer and the benign call rate of afirma gene classifier in 18 F-Fluorodeoxyglucose positron emission tomography positive cytologically indeterminate thyroid nodules.
Endo M, Sipos JA, Ringel MD, Porter K, Nagaraja HN, Phay JE, Shirley LA, Long C, Wright CL, Roll K, Nabhan FA
Cancer Med
October 27, 2020Akt isoform-specific effects on thyroid cancer development and progression in a murine thyroid cancer model.
Saji M, Kim CS, Wang C, Zhang X, Khanal T, Coombes K, La Perle K, Cheng SY, Tsichlis PN, Ringel MD
Sci Rep
September 25, 2020New Horizons: Emerging Therapies and Targets in Thyroid Cancer.
Ringel MD
J Clin Endocrinol Metab
August 11, 2020Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications.
Rajan N, Khanal T, Ringel MD
Endocrine
August 9, 2020Features of Cytologically Indeterminate Molecularly Benign Nodules Treated with Surgery.
Endo M, Porter K, Long C, Azaryan I, Phay JE, Ringel MD, Sipos JA, Nabhan F
J Clin Endocrinol Metab
August 7, 2020GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer.
Zhou W, Brumpton B, Kabil O, Gudmundsson J, Thorleifsson G, Weinstock J, Zawistowski M, Nielsen JB, Chaker L, Medici M, Teumer A, Naitza S, Sanna S, Schultheiss UT, Cappola A, Karjalainen J, Kurki M, Oneka M, Taylor P, Fritsche LG, Graham SE, Wolford BN, Overton W, Rasheed H, Haug EB, Gabrielsen ME, Skogholt AH, Surakka I, Davey Smith G, Pandit A, Roychowdhury T, Hornsby WE, Jonasson JG, Senter L, Liyanarachchi S, Ringel MD, Xu L, Kiemeney LA, He H, Netea-Maier RT, Mayordomo JI, Plantinga TS, Hrafnkelsson J, Hjartarson H, Sturgis EM, Palotie A, Daly M, Citterio CE, Arvan P, Brummett CM, Boehnke M, de la Chapelle A, Stefansson K, Hveem K, Willer CJ, Åsvold BO
Nat Commun
July 1, 2020p21-activated kinases in thyroid cancer.
Bautista L, Knippler CM, Ringel MD
Endocrinology
June 1, 2020The state of science in medullary thyroid carcinoma: current challenges and unmet needs.
Dadu R, Bagheri-Yarmand R, Ringel MD, Grubbs EG, Zafereo M, Cote GJ, Gagel RF, Robinson BG, Shaw KR, Hu MI
Endocr Relat Cancer
April 23, 2020Stromal platelet-derived growth factor receptor-β signaling promotes breast cancer metastasis in the brain.
Thies KA, Hammer AM, Hildreth BE, Steck SA, Spehar JM, Kladney RD, Geisler JM, Das M, Russell LO, Bey JF, Bolyard CM, Pilarski R, Trimboli AJ, Cuitiño MC, Koivisto CS, Stover DG, Schoenfield L, Otero J, Godbout J, Chakravarti A, Ringel MD, Ramaswamy B, Li Z, Kaur B, Leone G, Ostrowski MC, Sizemore ST, Sizemore GM
Cancer Res
March 4, 2020Assessing thyroid cancer risk using polygenic risk scores.
Liyanarachchi S, Gudmundsson J, Ferkingstad E, He H, Jonasson JG, Tragante V, Asselbergs FW, Xu L, Kiemeney LA, Netea-Maier RT, Mayordomo JI, Plantinga TS, Hjartarson H, Hrafnkelsson J, Sturgis EM, Brock P, Nabhan F, Thorleifsson G, Ringel MD, Stefansson K, de la Chapelle A
Proc Natl Acad Sci U S A
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Ringel has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- National Institutes of Health
- The Endocrine Society
- Society for Endocrinology and Bioscientifica
- Beth Israel Deaconness
- University of Virginia
Patient Comments
He may be my new favorite doctor. He was so nice. And he took so much time explaining everything to me and making me feel so much more comfortable with everything.
Personable, always willing to answer questions, professional, makes my visit comfortable because of his positivity. Such a kind doctor!
Very thorough, professional and supportive. We have complete faith in Dr. Ringel. He is an exemplary physician and leader in his profession.
Great
Excellent care providers!
I have thee utmost confidence in Dr. Ringel.
Could not ask for better care/staff
Ten stars every visit
Dr. Ringel and his team are always courteous, friendly and caring.
Dr is very knowledgeable. Glad I have him.
Dr. Ringel and his team are the best!
Dr ringel is one of the best doctors I've encountered. He explains in very understanding terms and spends just the right amount of time with you answering all questions
Over the years of care, Dr. Ringel and his team have been consistently competent, caring, patient and kind. Dr. Ringel always explains information in a clear understandable manner... He's the BEST!!
Dr. Ringel is wonderful. He always takes his time and shows real concern for my situation.
The quality of the care I have received is outstanding and has been consistently for the years I have been coming here.